<DOC>
	<DOCNO>NCT00376883</DOCNO>
	<brief_summary>Multiple myeloma malignant hematological disease dominate monoclonal plasma cell bone marrow . Major symptom relate bone due increase bone resorption decrease bone formation lead bone pain increase risk fracture . The normal osteoclast responsible bone degradation stimulation malignant plasma cell . Bisphosphonates show inhibit osteoclast activity may serious side-effects due renal toxicity optimal dose establish . In randomized double blind design aim compare standard monthly injection 90 mg pamidronate 30 mg . The primary end-point physical function estimate EORTC QLQ-C30 questionnaire 12 month start treatment newly diagnose treatment demand multiple myeloma . Secondary end-points skeletal related event , cost-utility analysis , response , response duration survival quality life respect fatigue pain .</brief_summary>
	<brief_title>Pamidronate Prophylaxis Multiple Myeloma 30 mg/Month Versus 90 mg/Month</brief_title>
	<detailed_description>Patients newly diagnose treatment demand multiple myeloma informed consent approve inclusion criterion randomise telephone call Copenhagen Trial Unit ( CTU ) information target dose send distributor , Amgros , local pharmacy preparation pamidronate solution . Infusion give 2½ hour . Before start treatment patient fulfil first EORTC QLQ-C30 questionnaire send quality life secretariat Oslo , Norway . Subsequent questionnaire mail directly patient every third month . The infusion continue 3 year may extend upon patient ’ request . Every third month number skeletal event , response complication record . Skeletal X-rays perform 9 24 month start treatment .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>New diagnose multiple myeloma treatment demand disease Lifeexpectancy le 3 month , another active malignant disease , treatment bisphosphonates 3 month within last 6 month , patient creatinine 400 µmol/l 4 week start chemotherapy , patient cooperate monthly infusion , patient give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>pamidronate prophylaxis</keyword>
	<keyword>dose comparison</keyword>
	<keyword>quality life</keyword>
	<keyword>skeletal event</keyword>
	<keyword>response</keyword>
	<keyword>survival</keyword>
</DOC>